...
首页> 外文期刊>Journal of endovascular therapy: an official journal of the International Society of Endovascular Specialists >Evaluation of the Biodegradable Igaki-Tamai Scaffold After Drug-Eluting Balloon Treatment of De Novo Superficial Femoral Artery Lesions: The GAIA-DEB Study
【24h】

Evaluation of the Biodegradable Igaki-Tamai Scaffold After Drug-Eluting Balloon Treatment of De Novo Superficial Femoral Artery Lesions: The GAIA-DEB Study

机译:药物洗脱球囊治疗De Novo股浅动脉病变后可生物降解的Igaki-Tamai支架的评估:GAIA-DEB研究

获取原文
获取原文并翻译 | 示例
           

摘要

Purpose: To evaluate the safety and efficacy of the Igaki-Tamai biodegradable scaffold after drug-eluting balloon (DEB) angioplasty in patients with occlusive superficial femoral artery (SFA) disease. Methods: A prospective, single-center, nonrandomized study enrolled 20 patients (mean age 66.7 +/- 11.6 years; 14 men) with symptomatic de novo SFA lesions undergoing angioplasty with the In.Pact Admiral paclitaxel-coated balloon and subsequent implantation of the Igaki-Tamai bioresorbable scaffold. All patients were claudicants. The average diameter stenosis was 89.7%, and the mean length was 43.6 mm. Clinical examinations with duplex sonography were performed after 1, 6, 9, and 12 months. The main study outcomes were technical success, restenosis, target lesion revascularization (TLR), ankle-brachial index (ABI) improvement, and changes in quality of life evaluated with the walking impairment questionnaire. Safety was assessed by monitoring the occurrence of adverse events. Results: Angioplasty with a paclitaxel-coated balloon was performed in all patients, resulting in an average diameter stenosis of 24%. Subsequent implantation of the Igaki-Tamai scaffold reduced the average diameter stenosis to 3.5%. In the first 6 months, 2 cases of restenosis were reported, with no TLRs within that period. However, by the 12-month follow-up in 19 patients, 11 patients had lost in-stent patency. Among these patients, 8 had TLRs, which were the only adverse events recorded that were referable to the procedure. Quality-of-life assessments showed improvement in the majority of patients. Conclusion: The GAIA-DEB study shows that DEB treatment of the femoral artery prior to the implantation of the biodegradable Igaki-Tamai scaffold is safe. However, the antiproliferative actions of paclitaxel in the vessel wall were not effective in preventing restenosis. In-stent restenosis occurred predominantly after 6 months.
机译:目的:评估药物洗脱球囊(DEB)血管成形术后Igaki-Tamai可降解支架在闭塞性股浅动脉(SFA)疾病中的安全性和有效性。方法:一项前瞻性,单中心,非随机研究纳入20例有症状的新生SFA病变的患者(平均年龄66.7 +/- 11.6岁; 14例男性),他们接受In.Pact海军上将紫杉醇涂层球囊成形术并随后植入Igaki-Tamai生物可吸收支架。所有患者均为老套。平均直径狭窄为89.7%,平均长度为43.6 mm。在1、6、9和12个月后进行双相超声检查。主要研究结果是技术成功,再狭窄,目标病变血运重建(TLR),踝臂指数(ABI)改善以及通过步行障碍问卷评估的生活质量变化。通过监测不良事件的发生来评估安全性。结果:所有患者均进行了紫杉醇涂层球囊血管成形术,平均狭窄度为24%。随后植入Igaki-Tamai支架可将平均直径狭窄降至3.5%。在最初的6个月中,报告了2例再狭窄病例,在此期间没有TLR。然而,通过对19例患者的12个月随访,有11例患者失去了支架内通畅。在这些患者中,有8位患有TLR,这是唯一记录的与该手术相关的不良事件。生活质量评估显示大多数患者的病情改善。结论:GAIA-DEB研究表明,在可生物降解的Igaki-Tamai支架植入之前,对股动脉进行DEB治疗是安全的。然而,紫杉醇在血管壁中的抗增殖作用不能有效地预防再狭窄。支架内再狭窄主要发生在6个月后。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号